Description
AZM198 is a selective, orally active, and irreversible MPO inhibitor with an IC50 of 15.0 nM. AZM198 has an IC50 of 19 µM for CYP3A4. AZM198 has favorable lipophilicity, membrane permeability, metabolic stability, safety, and pharmacokinetic properties. AZM198 exhibits activity in improving vascular function, atherosclerotic plaques, pulmonary hypertension, kidney disease, visceral inflammatory fat deposition, ectopic fat deposition, and hepatic fibrosis[1]